Stock Analysis

Inari Medical Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Published
NasdaqGS:NARI

Inari Medical (NASDAQ:NARI) Third Quarter 2024 Results

Key Financial Results

  • Revenue: US$153.4m (up 21% from 3Q 2023).
  • Net loss: US$18.4m (down from US$3.16m profit in 3Q 2023).
  • US$0.32 loss per share (down from US$0.055 profit in 3Q 2023).
NasdaqGS:NARI Earnings and Revenue Growth October 30th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Inari Medical Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 1.8%. Earnings per share (EPS) missed analyst estimates by 68%.

Looking ahead, revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Medical Equipment industry in the US.

Performance of the American Medical Equipment industry.

The company's shares are up 11% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Inari Medical has 1 warning sign we think you should be aware of.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.